| Literature DB >> 32430026 |
Elisa Gentilotti1,2, Pasquale De Nardo3,4, Boniface Nguhuni3,4, Alessandro Piscini3,4, Caroline Damian5, Francesco Vairo3, Zainab Chaula4, Paola Mencarini3, Peter Torokaa4, Alimuddin Zumla6,7, Emanuele Nicastri3, Giuseppe Ippolito3.
Abstract
BACKGROUND: Surgical site infections are a leading cause of morbidity and mortality after caesarean section, especially in Low and Middle Income Countries. We hypothesized that a combined infection prevention and control with antimicrobial stewardship joint program would decrease the rate of post- caesarean section surgical site infections at the Obstetrics & Gynaecology Department of a Tanzanian tertiary hospital.Entities:
Keywords: Antimicrobial resistance; Antimicrobial stewardship; Caesarean section; Resource-limited settings; Surgical site infection
Mesh:
Substances:
Year: 2020 PMID: 32430026 PMCID: PMC7236265 DOI: 10.1186/s13756-020-00740-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Four-steps protocol of the study. PRE-Int = pre-intervention; CS = caesarean section; SSI=Surgical Site Infections; DRRH = Dodoma Regional Referral Hospital; AMS = Antimicrobial stewardship; SOPs = Standard Operating Procedures; IPC=Infection Prevention and Control; ID = Infectious Diseases; OGD = Obstetrics & Gynaecology Department; POST-Int = post-intervention
Fig. 2Number of patients surveyed for post-CS SSI in the Pre-Intervention and Post-Intervention groups
Overall and per-groups analysis of surgical procedure and CS-SSI Characteristics
| Overall ( | PRE-Int ( | POST-Int ( | adj- | ||
|---|---|---|---|---|---|
| 0.059 | 0.170β | ||||
| Elective | 76 (7.3) | 42 (9.0) | 34 (5.9) | ||
| Emergency | 964 (92.7) | 425 (91.0) | 539 (94.1) | ||
| 0.043 | 0.155γ | ||||
| CS indication | 431 (41.4) | 209 (44.8) | 222 (38.7) | ||
| No CS indication | 606 (58.3) | 255 (54.6) | 351 (61.3) | ||
| Not known | 3 (0.3) | 3 (0.6) | 0 | ||
| 0.001 | 0.052 γ | ||||
| Senior | 345 (33.1) | 127 (27.2) | 218 (38.1) | ||
| Junior | 685 (65.9) | 337 (72.2) | 348 60.7) | ||
| Not known | 10 (1.0) | 3 (0.6) | 7 (1.2) | ||
| 0.000 | 0.001 γ | ||||
| Dettol | 2 (0.2) | 0 | 2 (0.3) | ||
| Ethanol | 94 (9.0) | 90 (19.3) | 4 (0.7) | ||
| Povidone/Iodine | 923 (88.8) | 366 (78.4) | 557 (97.2) | ||
| Not known | 21 (2.0) | 11 (2.4) | 10 (1.7) | ||
| 0.000 | 0.058 γ | ||||
| 247 (23.8) | 82 (17.6) | 165 (28.8) | |||
| Midline Vertical | 737 (70.9) | 341 (73.0) | 396 (69.1) | ||
| Not known | 56 (5.4) | 44 (9.4) | 12 (2.1) | ||
| 0.000 | 0.044 γ | ||||
| Silk (non-absorbable) | 693 (66.6) | 339 (72.6) | 354 (61.8) | ||
| Vicryl (absorbable) | 265 (25.5) | 91 (19.5) | 174 (30.4) | ||
| Not known | 82 (7.9) | 37 (7.9) | 45 (7.9) | ||
| 0.000 | 0.076 γ | ||||
| Interrupted | 700 (67.3) | 327 (70.0) | 373 (65.1) | ||
| Continuousintradermic and semisubcutaneous | 260 (26.0) | 96 (20.6) | 174 (30.4) | ||
| Not known | 70 6.7 | 44 (9.4) | 26 (4.5) | ||
| 0.000 | 0.000 γ | ||||
| No | 457 (43.9) | 451 (96.6) | 6 (1.0) | ||
| Yes | 572 (55.0) | 10 (2.1) | 562 (98.1) | ||
| Not Known | 11 (1.1) | 6 (1.3) | 5 (0.9) | ||
| 0.017 | 0.011 γ | ||||
| Appropriate | 162 (28.3) | 5 (50) | 157 (27.9) | ||
| Not appropriate | 372 (65) | 2 (20) | 370 (65.8) | ||
| Not known | 38 (6.7) | 3 (30) | 35 (6.3) | ||
| 0.000 | 0.000 γ | ||||
| No | 406 (39.0) | 4 (0.9) | 402 (70.2) | ||
| Yes | 627 (60.3) | 459 (98.2) | 168 (29.3) | ||
| Not Known | 7 (0.7) | 4 (0.9) | 3 (0.5) | ||
| 8.5, 1–38 (3.4) | 8.5, 2–37 (2.5) | 8.4, 1–38 (4.0) | 0.701 | ||
| 0.000 | 0.001 β | ||||
| Yes | 320 (30.8) | 225 (48.2) | 95 (16.6) | ||
| No | 720 (69.2) | 242 (51.8) | 478 (83.4) | ||
| 0.037 | 0.001 γ | ||||
| Yes | 224 (21.5) | 166 (73.8) | 58 (61.1) | ||
| No | 742 (71.3) | 57 (25.3) | 37 (38.9) | ||
| Not known | 2 (0.2) | 2 (0.9) | 0 | ||
| 0.000 | 0.045 γ | ||||
| Superficial | 218 (21.0) | 138 (61.3) | 80 (84.2) | ||
| Deep/involving organ and/or spaces | 85 (8.2) | 74 (32.9) | 11 (11.6) | ||
| Not known | 17 (1.6) | 13 (5.8) | 4 (4.2) |
CS caesarean section, SSI Surgical Site Infections; *Bonferroni adjusted p-value; β α = 0.012; γα = 0.008
Analysis of risk factors for SSI in patients undergoing CS in the PRE-Int and POST-Int groups and Overall
| Overall ( | PRE-Int ( | POST-Int ( | |||||||
|---|---|---|---|---|---|---|---|---|---|
| SSI ( | No SSI ( | SSI ( | No SSI ( | SSI ( | No SSI ( | ||||
| 0.403 | 0.561 | 0.009 | |||||||
| < 20 | 58 (35.2) | 107 (64.8) | 33 (43.4) | 43 (56.6) | 25 (28.1) | 64 (71.9) | |||
| 21–34 | 220 (29.9) | 516 (70.1) | 164 (48.4) | 175 (51.6) | 56 (14.1) | 341 (85.9) | |||
| > 34 | 39 (29.8) | 92 (70.2) | 27 (52.9) | 24 (47.1) | 12 (15.0) | 68 (85.0) | |||
| Not known | 1 (100) | 0 | 2 (28.6) | 5 (71.4) | |||||
| 27.8 (14–46) | 26.9 (16–66) | 0.031 | 27.7 (19–46) | 26.7 (18–45) | 0.060 | 27.8 (14–41) | 27 (16–66) | 0.224 | |
| 0.327 | 0.518 | 0.621 | |||||||
| No | 46 (35.1) | 85 (64.9) | 34 (51.5) | 32 (48.5) | 12 (18.5) | 53 (81.5) | |||
| Standard 7a | 165 (31.2) | 364 (68.8) | 112 (46.5) | 129 (53.5) | 53 (18.4) | 235 (81.6) | |||
| Form I-VIb | 88 (30.4) | 201 (69.6) | 68 (51.5) | 64 (48.5) | 20 (12.7) | 137 (87.3) | |||
| College/University | 16 (21.1) | 60 (78.9) | 7 (33.3) | 14 (66.7) | 9 (16.4) | 46 (83.6) | |||
| Not known | 5 (33.3) | 10 (66.7) | 4 (57.1) | 3 (42.9) | 1 (12.5) | 7 (87.5) | |||
| 0.097 | 0.462 | 0.104 | |||||||
| Yes | 16 (44.4) | 20 (55.6) | 10 (58.8) | 7 (41.2) | 6 (31.6) | 13 (68.4) | |||
| No | 295 (30.4) | 676 (69.6) | 211 (48.2) | 227 (51.8) | 84 (15.8) | 449 (84.2) | |||
| Not known | 9 (27.3) | 24 (72.7) | 4 (33.3) | 8 (66.7) | 5 (23.8) | 16 (76.2) | |||
| 0.607 | 0.469 | 0.338 | |||||||
| Elective | 21 (27.6) | 55 (72.4) | 18 (42.9) | 24 (57.1) | 3 (8.8) | 31 (91.2) | |||
| Emergency | 299 (21.0) | 665 (69.0) | 207 (48.7) | 218 (51.3) | 92 (17.1) | 447 (82.9) | |||
| 0.801 | 0.558 | 0.084 | |||||||
| Previously knownc | 133 (30.8) | 299 (69.2) | 104 (49.5) | 106 (50.5) | 29 (13.1) | 193 (86.9) | |||
| Not previously known | 187 (30.8) | 420 (69.2) | 121 (47.3) | 135 (52.7) | 66 (18.8) | 285 (81.2) | |||
| 0.006 | 0.038 | 1.000 | |||||||
| Junior | 229 (33.4) | 456 (66.6) | 172 (51.0) | 165 (49.0) | 57 (16.4) | 291 (83.6) | |||
| Senior | 87 (25.2) | 258 (74.8) | 51 (40.2) | 76 (59.8) | 36 (16.5) | 182 (83.5) | |||
| < 0.001 | 0.410 | 1.000 | |||||||
| Dettol/Ethanol | 48 (50.0) | 48 (50.0) | 47 (52.2) | 43 (47.8) | 1 (16.7) | 5 (83.3) | |||
| Povidone-Iodine | 265 (28.7) | 658 (71.3) | 172 (47.0) | 194 (53.0) | 93 (16.7) | 464 (83.3) | |||
| < 0.001 | < 0.001 | < 0.001 | |||||||
| Midline Vertical | 280 (38.0) | 457 (62.0) | 198 (58.1) | 143 (41.9) | 82 (20.7) | 152 (92.1) | |||
| 37 (15.0) | 210 (85.0) | 24 (29.3) | 58 (70.7) | 13 (7.9) | 314 (79.3) | ||||
| < 0.001 | 0.370 | 0.006 | |||||||
| Silk | 237 (34.2) | 456 (65.8) | 167 (49.3) | 172 (50.7) | 70 (19.8) | 284 (80.2) | |||
| Vicryl (absorbable) | 58 (21.9) | 207 (78.1) | 40 (44.0) | 51 (56.0) | 18 (10.3) | 156 (89.7) | |||
| < 0.001 | < 0.001 | < 0.001 | |||||||
| Interrupted | 268 (38.3) | 432 (61.7) | 190 (58.1) | 137 (41.9) | 78 (20.9) | 295 (79.1) | |||
| Continuous intradermic and semisubcutaneous | 45 (16.7) | 225 (83.3) | 31 (32.3) | 65 (67.7) | 14 (8.0) | 160 (92.0) | |||
| < 0.001 | 1.000 | 1.000 | |||||||
| No | 216 (47.3) | 241 (52.7) | 215 (47.7) | 236 (52.3) | 1 (16.7) | 5 (83.3) | |||
| Yes | 97 (17.0) | 475 (83.0) | 5 (50.0) | 5 (50.0) | 92 (16.4) | 470 (83.6) | |||
| 0.548 | 0.428 | 0.307 | |||||||
| Adequate | 25 (27.2) | 137 (31) | 3 (100) | 2 (50) | 22 (24.7) | 135 (30.8) | |||
| Not adequate | 67 (72.8) | 305 (69) | 0 | 2 (50) | 67 (75.3) | 303 (69.2) | |||
| < 0.001 | 1.000 | 0.220 | |||||||
| No | 64 (15.8) | 342 (84.2) | 2 (50.0) | 2 (50.0) | 62 (15.4) | 340 (84.6) | |||
| Yes | 253 (40.4) | 374 (59.6) | 220 (47.9) | 239 (52.1) | 33 (19.6) | 135 (80.4) | |||
aPrimary education; bSecondary education; ccephalopelvic disproportion, bad obstetric history, previous CS
Overall and per-groups analysis of microbiological characteristics
| Overall SSI ( | PRE-Int SSI ( | POST-Int SSI ( | ||
|---|---|---|---|---|
| Yes | 280 (87.5) | 197 (87.5) | 83 (87.4) | |
| No | 40 (12.5) | 28 (12.5) | 12 (12.6) | |
| No bacterial growth | 112 (40) | 91 (45.2) | 21 (25.3) | |
| Bacterial Growth | 168 (60) | 106 (53.8) | 62 (74.7) | |
| Gram-positive | 127 (75.6) | 90 (84.9) | 37 (59.7) | |
| Gram-negative | 41 (24.4) | 16 (15.1) | 25 (40.3) | |
| 57 (44.9) | 43 (40.6) | 14 (37.9) | ||
| 57 (44.9) | 47 (44.4) | 10 (27.0) | ||
| 3 (2.4) | 0 | 3 (8.1) | ||
| 10 (7.8) | 0 | 10 (27.0) | ||
| 4 (9.8) | 1 (6.3) | 3 (12.0) | ||
| 4 (9.8) | 3 (18.7) | 1 (4.0) | ||
| 11 (26.8) | 4 (25.0) | 7 (28.0) | ||
| 6 (14.6) | 1 (6.3) | 5 (20.0) | ||
| 16 (39.0) | 7 (43.7) | 9 (36.0) | ||
MRSA Methicillin-Resistant Staphylococcus aureus, MDROs Multidrug Resistant Organisms